Pay in 4 interest-free payments of $6.58 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase I clinical study
Delta sleepinducing peptide (DSIP): a still unresolved riddle
First, lack of exposure is possible, as we lacked information on patient compliance with prescribed treatments and potential lack of medication dispensed at hospitals, however as medication compliance is similar across all three groups and we defined exposure as redeemed prescriptions, ensuring that the medication was actively collected by the patient, systematic misclassification is unlikely
Kaugars GE, Heise AP, Riley WT, Abbey LM, Svirsky JA
US$ 21.07
US$ 26.78
US$ 25.12
US$ 29.75
US$ 29.76
US$ 26.11
